Zydus announces USFDA Orphan Drug Designation to Usnoflast for treatment of ALS
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
Visby Medical’s instrument-free PCR test to detect the SARS-CoV-2 virus can now be used to pool up to five patient samples using a single test
New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson Covid-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.
Subscribe To Our Newsletter & Stay Updated